CIViC Compass
Research use only — not FDA-cleared, not medical advice. Always consult FDA-approved labeling and a qualified clinician.

CIViC Evidence Items

43 evidence items indexed

Evidence Level Distribution

CIViC evidence levels reflect study design quality, from A (strongest) to E (weakest).

AValidated — meta-analysis, systematic review, or major guideline
BClinical — prospective trial or retrospective cohort study
CCase study — single case report or small case series
DPreclinical — in vitro or animal model data
EInferential — computational prediction or biological rationale

Gene × Evidence Type

Count of CIViC evidence items per gene and evidence type category. Hover a column header for the type definition.

PredictiveDiagnosticPrognosticFunctionalPredispos.Oncogenic
BCR::ABL132311
BRAF18642621
EGFR2481232
EML4::ALK64
ERBB21422
FLT355221
KIT10237
KRAS1594244
PIK3CA156164
PTEN5313121
TP5352401002
VHL52363515
Predictive:Links a variant to treatment response or resistance
Diagnostic:Supports or refutes a specific disease diagnosis
Prognostic:Informs disease progression or clinical outcome
Functional:Characterises the biological effect of a variant
Predisposing:Germline variant associated with cancer predisposition
Oncogenic:Characterises the variant's role in oncogenesis
Clear
LevelGeneVariantTypeDirectionSignificanceDiseaseDrugsSource
DFGFR1AmplificationPredictiveSupportsSensitivity/ResponseLung Squamous Cell CarcinomaPD173074Weiss et al., 2010
BFGFR1AmplificationPrognosticSupportsPoor OutcomeBreast CancerO'Leary et al., 2021
BFGFR1AmplificationPrognosticSupportsPoor OutcomeBreast CancerMouron et al., 2021
DFGFR1AmplificationPredictiveSupportsSensitivity/ResponseBreast CancerFulvestrant,Rogaratinib,PalbociclibMouron et al., 2021
DFGFR1ExpressionPredictiveSupportsSensitivity/ResponseLung CancerPonatinibWynes et al., 2014
BFGFR1AmplificationPrognosticSupportsPoor OutcomeLung Squamous Cell CarcinomaKim et al., 2013
BFGFR1AmplificationPrognosticSupportsPoor OutcomeCancerChang et al., 2014
DFGFR1AmplificationPredictiveSupportsSensitivity/ResponseLung Non-small Cell CarcinomaPD173074Dutt et al., 2011
BFGFR1AmplificationPrognosticDoes Not SupportPoor OutcomeLung Squamous Cell CarcinomaJiang et al., 2015
BFGFR1Internal DuplicationDiagnosticSupportsPositiveChildhood Low-grade GliomaZhang et al., 2013
DFGFR1Amplification OR FGFR1 OverexpressionPredictiveSupportsResistanceEstrogen-receptor Positive Breast CancerCDK4/6 Inhibition,Antiestrogen TherapyFormisano et al., 2019
BFGFR1AmplificationPrognosticSupportsPoor OutcomeLung Squamous Cell CarcinomaSeo et al., 2014
DFGFR1ExpressionPredictiveSupportsSensitivity/ResponseHead And Neck Squamous Cell CarcinomaInfigratinibGöke et al., 2015
DFGFR1AmplificationPredictiveSupportsResistanceBreast CancerAfimoxifeneTurner et al., 2010
DFGFR1AmplificationPredictiveSupportsSensitivity/ResponseEwing Sarcoma Of BonePonatinibAgelopoulos et al., 2015
DFGFR1AmplificationPredictiveSupportsSensitivity/ResponseEstrogen-receptor Positive Breast CancerPonatinibGozgit et al., 2012
BFGFR1AmplificationPredictiveSupportsSensitivity/ResponseLung Squamous Cell CarcinomaInfigratinibNogova et al., 2017
DFGFR1ExpressionPredictiveSupportsSensitivity/ResponseSarcomaFexagratinib,Infigratinib,FGF/VEGF Receptor Tyrosine Kinase Inhibitor, PD173074Chudasama et al., 2017
BFGFR1AmplificationPredictiveSupportsSensitivity/ResponseBreast CancerLucitanibSoria et al., 2014
CFGFR1AmplificationPredictiveSupportsSensitivity/ResponseAdenosquamous Lung CarcinomaPazopanibMalchers et al., 2014
CFGFR1N546KPredictiveSupportsSensitivity/ResponsePilocytic AstrocytomaPemigatinibCapone et al., 2022
BFGFR1AmplificationPrognosticSupportsPoor OutcomeBreast CancerErber et al., 2020
BFGFR1AmplificationPredictiveSupportsSensitivity/ResponseBreast CancerEverolimus,Endocrine Drug TherapyDrago et al., 2019
CFGFR1AmplificationPredictiveDoes Not SupportSensitivity/ResponseBreast CancerPemigatinibRodón et al., 2024
DFGFR1AmplificationPredictiveSupportsSensitivity/ResponseBreast CancerFutibatinibSootome et al., 2020
BFGFR1AmplificationPrognosticSupportsBetter OutcomeLung Non-small Cell CarcinomaTran et al., 2013
BFGFR1ExpressionPrognosticSupportsPoor OutcomeBreast CancerShi et al., 2016
DFGFR1ExpressionPredictiveSupportsSensitivity/ResponseGastric AdenocarcinomaInfigratinibSchmidt et al., 2015
DFGFR1ExpressionPredictiveSupportsSensitivity/ResponseBladder CarcinomaPD173074,DovitinibLamont et al., 2011
DFGFR1ExpressionPredictiveSupportsSensitivity/ResponseColorectal CancerInfigratinibGöke et al., 2013
BFGFR1ExpressionPrognosticSupportsPoor OutcomeHead And Neck Squamous Cell CarcinomaHase et al., 2006
EFGFR1N546KPredictiveSupportsSensitivity/ResponseEwing Sarcoma Of BonePonatinibAgelopoulos et al., 2015
BFGFR1AmplificationPredictiveSupportsSensitivity/ResponseBreast CancerDovitinibAndré et al., 2013
BFGFR1AmplificationPredictiveDoes Not SupportResistanceBreast CancerInfigratinibNogova et al., 2017
CFGFR1AmplificationPredictiveDoes Not SupportSensitivity/ResponseBladder CarcinomaInfigratinibNogova et al., 2017
CFGFR1AmplificationPredictiveSupportsSensitivity/ResponseBreast CancerFexagratinibPearson et al., 2016
BFGFR1AmplificationPredictiveSupportsSensitivity/ResponseLung Non-small Cell CarcinomaDovitinibLim et al., 2016
CFGFR1AmplificationPredictiveSupportsSensitivity/ResponseBreast CancerPazopanibCheng et al., 2017
BFGFR1AmplificationPredictiveSupportsSensitivity/ResponseBreast CancerErdafitinibGong et al., 2024
BFGFR1AmplificationPredictiveSupportsSensitivity/ResponseBreast CancerDovitinibMusolino et al., 2017
BFGFR1AmplificationPredictiveDoes Not SupportSensitivity/ResponseBreast CancerSunitinibCalfa et al., 2024
DFGFR1AmplificationPredictiveSupportsBreast CancerLucitanib,RogaratinibSánchez-Guixé et al., 2022
BFGFR1ExpressionPrognosticSupportsPoor OutcomeHead And Neck Squamous Cell CarcinomaIpenburg et al., 2016